🇺🇸 combined treatment in United States

FDA authorised combined treatment on 28 July 1997

Marketing authorisations

FDA — authorised 28 July 1997

  • Application: NDA020381
  • Marketing authorisation holder: ABBVIE
  • Local brand name: NIASPAN
  • Indication: TABLET, EXTENDED RELEASE — ORAL
  • Status: approved

Read official source →

FDA

  • Status: approved

combined treatment in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is combined treatment approved in United States?

Yes. FDA authorised it on 28 July 1997; FDA has authorised it.

Who is the marketing authorisation holder for combined treatment in United States?

ABBVIE holds the US marketing authorisation.